Genes based on thalidomide, valproic acid and methotrexate treatment for screening of drug inducing teratogenicity and screening method using thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 21, 2013
Grant Date -
Oct 7, 2010
app pub date -
Apr 7, 2009
filing date -
Apr 7, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a screening method using the genes related to teratogenicity, more precisely the genes up- or down-regulated by a drug inducing teratogenicity such as thalidomide, valproic acid, and methotrexate and a method for screening of thalidomide, valproic acid and methotrexate using the genes. The genes of the present invention is based on reactive genes selected by DNA microarray chip, so that it is very effective in risk assessment and monitoring drugs or chemicals having high risk of teratogenicity and at the same time it can be used as a tool to examine mechanism of teratogenicity.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully